Availability of platelet-rich plasma for treatment of erectile dysfunction and associated costs and efficacy: A review of current publications and Canadian data

Deron Britt, BSc1; Udi Blankstein, MD2; Matthew Lenardis, MD2; Alexandra Millman, MD2; Ethan Grober, MD3; Yonah Krakowsky, MD3

1University of Ottawa, Faculty of Medicine, Ottawa, ON, Canada; 2Division of Urology, University of Toronto, Toronto, ON, Canada; 3Women’s College Hospital, Division of Urology, University of Toronto, Toronto, ON, Canada

Cite as: Britt D, Blankstein U, Lenardis M, et al. Availability of platelet-rich plasma for treatment of erectile dysfunction and associated costs and efficacy: A review of current publications and Canadian data. Can Urol Assoc J 2021;15(6):202-6. http://dx.doi.org/10.5489/cuaj.6947

Published online November 17, 2020

Abstract

Introduction: Platelet-rich plasma (PRP) is an increasingly used unconventional treatment option for erectile dysfunction (ED). The validity of PRP as a potential treatment for ED has been proposed in limited human trials. Furthermore, the costs associated with PRP for ED treatment are not readily promoted to patients. The goal of this review was to determine the efficacy and costs of PRP based on currently available literature and Canadian data.

Methods: A comprehensive literature review of available PRP studies and current published data pertaining to cost, availability, and provider clinics globally was conducted using the PubMed database. Physicians offering genital PRP in Canada were identified using internet searches and PRP provider directories. Physician qualifications, clinic locations, and cost information were obtained from provider websites and telephone calls to identified clinics.

Results: Availability of PRP injections offered for treating ED is increasing globally. There are currently no peer-reviewed publications to substantiate anecdotal evidence pertaining to the efficacy of PRP as a viable treatment option for ED patients. Our results indicate 19 providers for PRP injections in Canada, costing on average $1777 CAD per injection. No providers were affiliated with academic institutions and providers varied in their area of clinical speciality and training.

Conclusions: To our knowledge, there is currently no research underway investigating the clinical efficacy of PRP for ED treatment despite its broad availability and significant cost. Patients should be informed of the lack of substantiated efficacy and safety data, as the reliability of PRP treatments requires further evaluation.

Introduction

Erectile dysfunction (ED) is a common condition defined as the inability to initiate or sustain an erection and is estimated to affect over 300 million men globally by 2025. Estimates of ED in the general population vary greatly, from 3–76.5%, but it is known to be substantially more persistent in aging demographics, with prevalence greater than 50% in men aged 40–70 years. In the U.S., approximately 12 million men suffer from ED influenced by common comorbidities, including diabetes mellitus (DM), hypertension, and obesity. Although there are discrepancies among studies, ED specifically after invasive urological procedures, including radical prostatectomy (RA), has been documented to be as high as 85%. Compounding the physical limitations of ED, high rates of emotional distress and depression have also been documented in large-scale population studies globally. Recently, platelet-rich plasma (PRP) intracavernosal injections have been increasing in demand as a potential treatment modality for ED patients, despite limited data to demonstrate continuous efficacy and safety in long-term trials. With a growing demand for alternative treatment options for patients, including low-intensity extracorporeal shockwave lithotripsy (LI-ESWL) and stem cell treatment (SCT), there is also a corresponding lack of standardized costs to patients through marketing from clinics supplying treatment options. The publications currently available, related to human clinic trials and availability of treatment, are limited in regards to total costs of treatment, providers, and professional affiliation.

To our knowledge, there are currently no publications of Canadian data pertaining to PRP injection clinics and associated costs to patients. This study will review the current efficacy and safety surrounding PRP injections for ED patients, as well as investigate PRP injection for ED providers and treatment costs in Canada.
Use of platelet-rich plasma for treatment of ED

Methods

Literature review

Literature review searches were performed using the PubMed database with the initial following MeSH terms: “platelet-rich plasma” AND “erectile dysfunction.” Twenty results were initially found from those MeSH terms and only peer-reviewed publications were used in this study. Both free full-texts and texts requiring access to certain journals were used. Following the initial MeSH search, a second screening was initiated using the PubMed database and the MeSH terms: “platelet-rich plasma” AND “safety and efficacy.” Sixty-eight results were compiled from the MeSH terms and publications were selected based on relevance to PRP studies and chronological order of publication. Supplementary publications on the usage, efficacy, and safety pertaining to phosphodiesterase inhibitors and their subsequent mechanistic properties referenced in this review were collected from peer-reviewed publications found in the original MeSH search.

Data analysis

Physicians offering PRP injections for treatment of ED in Canada were identified using Internet searches and PRP provider directories. Physician qualifications, clinic locations, and cost information were obtained from provider websites and telephone calls to identified clinics.

Results

Eighteen providers were identified across Canada that offered PRP injections for treating ED. The mean cost of a single treatment was $1777 CAD (range $650–2500). All clinics recommended at least two treatments for optimal results. No information was available regarding adverse effects or contraindications to treatment. Providers were trained in family medicine (n=10), naturopathic medicine (n=2), emergency medicine (n=2), urology (n=1), internal medicine (n=1), anesthesiology (n=1), and unreported (n=1). Providers were located in Ontario (n=8), Alberta (n=6), Quebec (n=2), British Columbia (n=1), and Saskatchewan (n=1). No PRP provider had a university/academic affiliation.

Discussion

PRP: A historical perspective

PRP has been used as a treatment option in multiple medical specialities, including plastic surgery, otolaryngology, and orthopedic surgery since the 1980s. PRP is theorized to provide regenerative capacity to tissues through introduction of autologous plasma with augmented platelet concentrations that far surpass that of normal blood levels. These levels of platelets introduce amplified quantities of growth factors that are critical to providing stimulation for tissue repair. PRP-related growth factors include, but are not limited to, insulin growth factor-1 (IGF-1), transforming growth factor β (TGF-β), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF). These proposed regenerative qualities have made PRP a rapidly growing, unconventional therapy option for tissue regeneration in the context of, but not limited to, musculoskeletal repair, endometrial and follicular growth, cardiovascular applications, and hair loss in other medical specialties.

The process of PRP preparation and extraction of corresponding essential growth factors in inactive and activated forms has been detailed extensively in previous studies. Recently, PRP has also been used as a treatment for ED and other urological conditions, due in part to studies showcasing positive treatment results in other subspecialties of medicine (i.e., orthopedic and cardiac surgery). The multitude of PRP-contained growth factors have been determined to play regenerative roles via angiogenesis, collagen synthesis, restoration of smooth muscle cells, and a variety of other biochemical functions. While this has been extensively theorized for the use in other medical specialities, it has only been studied for urological purposes in limited ways, predominately in animal models, and has currently not demonstrated consistent improvement in human trials.

Role in ED

In the context of ED, PRP-associated growth factors have been most comprehensively studied to establish their effects on erectile function via neurogenic pathways. Clinically, trauma related urethral injuries and RP are just two mechanisms to indirectly instigate cavernous nerve injury (CNI), leading to neurogenic ED. CNI precipitates a decrease in density of nitric oxide synthase (NOS)-rich nerve regions, subsequently leading to numerous biochemical events initiating smooth muscle and endothelial cell death. Corresponding fibrosis of cavernous smooth muscle increases potential constriction of penile tissue, decreasing probability of induction or sustainment of erection. Penile erection is mediated by nitric oxide (NO) and NOS, both of which are critical for the initiation and maintenance of erections. The proposed effects of neurotrophic growth factors, like VEGF or IGF-1, on improvement of erectile function suggest their capability of increasing downregulated gene expression fundamental to improving erectile quality through these or similar pathways. Increasing NO, and subsequent conversion to cGMP, is vital in promoting relaxation of corpus caver-
nus smooth muscle and promoting effective vasodilation to sustain penile erection.\textsuperscript{28,29} As an example, phosphodiesterase 5 (PDE5) inhibitors (i.e., sildenafil or vardenafil) limit the breakdown of cGMP, leading to prolonged elevated cGMP levels in erectile tissue and sustained penile erections.\textsuperscript{29} These pharmaceutical agents, however, have been a proven treatment method through long-term followup studies, standardized dosing protocols, and safety trials in large cohort studies, and are presently considered effective and safe treatment agents for patients.\textsuperscript{10-33}

**Animal model trials**

Efficacy for ED treatment involving PRP has been primarily investigated in animal trials via cavernous nerve crush injury or cavernous neurotomy studies.\textsuperscript{16} Multiple studies have demonstrated that PRP-associated growth factors are critical for increased neuronal nitric oxide synthase (nNOS), promoting neural regeneration and potential improvement in erectile function.\textsuperscript{16-21} Erectile function improvements in rat models have also been documented following PRP injections in groups with bilateral CNI.\textsuperscript{20} Intensified TGF-\(\beta\) 1 levels and axon preservation was documented in these studies at four-week followup, along with improved erectile function in the PRP-treated group.\textsuperscript{20} Optimized PRP, composed of increased levels of PDGF in subsequent studies, was found to improve recovery, as well as erectile function in groups who underwent bilateral CN crush injury.\textsuperscript{100} More recent studies in rat models have found similar trends in which increased myelination and improved erectile function suggest that growth factors, including TGF-\(\beta\), IGF-1, and VEGF, support regeneration of CNs and positively impact nNOS post-CNI.\textsuperscript{16}

**Human clinical trials**

There have been a limited number of human clinical trials investigating PRP in patients with ED to date. Epifanova et al, examined essential growth factors for improving erectile function in ED patients from PRP samples obtained from control (n=12) and patient (n=12) groups. Concentrations of growth factors from both population groups were identified through flow cytometry, with results of the study indicating that the overall concentration of growth factors was higher in the control group (1,480) when compared to the patient group (1,232), concluding that the improvements in erectile function proposed were due to the active contents of PRP obtained (i.e., FGF, PDGF, and VEGF).\textsuperscript{22}

The most recent human trials involving PRP have discussed the potential theoretical use for ED therapy, as well as other urological illnesses.\textsuperscript{23} However, the concerns surrounding early washout of PRP was considered in these trials, and the suggestion was made to convert PRP to platelet-rich fibrin matrix (PRFM) prior to injection in patients.\textsuperscript{23} Results of this study suggest there were no major complications found in the patient population (n=4) during followup, and pre- and post-injection International Index of Erectile Function (IIEF-5) scores did not indicate decline in the patient population.\textsuperscript{23} These studies have given promise to PRP being used as a treatment option for ED.

**Safety of PRP for ED treatment**

Investigations surrounding the safety of PRP injections as a form of regenerative therapy has been extensively discussed and reviewed in non-urology-based medical specialities in both human and animal population publications.\textsuperscript{34} The general consensus from these previous analyses suggests that PRP injections have been deemed as a safe modality for treatment in multiple practices of medicine that includes orthopedics, dermatology, musculoskeletal tissue regeneration, and other applications.\textsuperscript{34-36} Regarding the safety of PRP as a prospective therapy option for ED, evidence from small-group, animal-based studies involving novel rat models with experimentally induced neurogenic penile injuries has not shown the long-term effects on treated animals, and therefore, overall safety has not been verified.\textsuperscript{20,21}

The most recent available studies published on human clinical groups are limited in regards to both qualitative and quantitative data but do suggest that PRP injections can be a safe modality for treatment, with bruising at the site of injection being the only reported ill effect in short-term followup in a small percentage of test subjects.\textsuperscript{23} However, further investigations involving larger cohort studies, random control trials, and long-term followup of patients is critical to confirm or refute these conclusions.\textsuperscript{8}

**Efficacy of PRP for ED treatment**

PRP has been shown to improve erectile function in animal studies involving induced neurogenic ED in small-sample populations.\textsuperscript{37} However, these studies have not demonstrated long-term cessation of ED in animal models, and further improvement on standardized quantities of growth factors are required to substantiate efficacy of treatment. Furthermore, larger cohort studies would provide a broader population base to sample and improve validity of future results.\textsuperscript{5,23}

The available published trials that include human data have proposed that PRP could be provided as a plausible ED treatment option for patients from initial results demonstrating both their safety and efficacy post-injection.\textsuperscript{22,23} However, systematic analysis revealed extensive limitations in these studies due to small group sizes, short followup periods, the absence of control and placebo groups, and missing quality and quantity analysis of PRP.\textsuperscript{22-24,37} As such, review of the current published animal and human data sug-
gests there is no concrete evidence supporting the validity of PRP as a reliable technique for the treatment of ED. Similarly, available data pertaining to the efficacy of PRP injections in other medical subspecialties as a viable treatment modality is reflected as predominately anecdotal and found to be lacking both qualitative and quantitative corroborating evidence. Methods required for standardization of PRP processing and associated concentrations of growth factors, as well as more qualitative, randomized controlled trials involving larger patient cohorts and subsequent long-term followup investigations are necessary to properly assess efficacy and safety of treatment in patient populations diagnosed with ED and other urological conditions.

Availability of PRP in North America and internationally

Novel techniques and treatments for ED, including PRP, LI-ESWL, and SCT, are increasing in both availability and demand throughout Canada and internationally. Scott et al found that global trends in PRP-associated treatments for ED are steadily increasing in demand, primarily in Australia, New Zealand, and the U.S. The study systematically evaluated the marketing of PRP through various global providers and any trends associated with PRP and ED, including the availability of advertised products. Results of this analysis determined that the most accessible marketed forms of PRP injections for ED, including the Priapus shot or P-shot, had 683 providers registered in 19 countries at the time of their data acquisition. Most providers identified did not provide the costs of intra-cavernous injections of PRP marketed online to prospective patients and most providers of PRP were not certified urologists in any of the countries offering these injections. Given the increase in marketing of PRP for ED, as well as the increased interest from the public globally, greater transparency in regards to the efficacy and cost of injections is warranted, and larger scientific studies on patient populations are necessary to establish the current efficacy and safety of these procedures.

Canadian data

In regards to cost, availability, and clinical provider affiliations and trends associated with PRP injections in Canada, the data obtained in our study coincides with similar findings globally. Currently, the average cost per injection in Canada is estimated to be $1777 CDN, similar to Australia ($1500 AUD) and the U.S. ($1500–2200 USD). Out of the 18 PRP providers in Canada for the treatment of ED, a substantial portion (n=5) did not provide details regarding cost of treatment via promotional websites, coinciding with international marketing tendencies. Furthermore, all Canadian clinics (n=18) emphasized a minimum of two treatments to optimize results for men being treated for ED. Expenses affiliated with followup injections increased in cost or are not detailed, which follows a trend in previous publications declaring that multiple providers promote serial injections of PRP to maximize treatment efficacy. With the most recent published international data suggesting that PRP injections can cost thousands of dollars per treatment, and with no immediate government subsidization offered to patients or minimal regulation of unsubstantiated therapies, it is critical for patients to understand the current validity and safety associated with these methods.

Another revelation of the Canadian data that warrants further investigation was that none of the providers of PRP injections were found to be affiliated with any academic institutions. Insight as to why this may be could be of great value for future studies to explore. Patient understanding of the current information surrounding these methods can be improved in the future by educating patients in regards to the recent published efficacy and safety data pertaining to PRP, as well as the current peer-reviewed evidence either supporting or contrary to advertised treatments from clinical providers. Furthermore, transparency from clinics offering PRP treatment regarding the state of the evidence is vital for building patient rapport and obtaining informed consent. The costs associated with PRP injections, and potential followup or ancillary fees, are extensive and can place added financial, emotional, or physical stress on the patient, especially if PRP is unsuccessful.

Conclusions

PRP injections are an ever-increasing method advertised as a viable treatment for a variety of urological conditions, including male and female dysfunction, and more specifically, ED in the male population. PRP is available in most parts of Canada at a significant cost, with no university-affiliated providers currently offering PRP at the time of this review. To our knowledge, there is currently no research underway investigating its clinical efficacy to endorse its clinical use and corroborate limited human trials. Review of the current literature suggests there is currently not enough substantiated data to warrant PRP being a practical treatment option for patients suffering from ED. More extensive human trials that include standardized control groups and protocols, along with long-term followup data are necessary to provide further insight into whether PRP can be incorporated as a routine option for the treatment of ED.

Competing interests: Dr. Grober has been an investor for NHB Labs, a research supporter for Boston Scientific, and a consultant for Paladin. Dr. Krakowsky has been a consultant for Paladin, Verity, and Pfizer. The remaining authors report no competing personal or financial interests related to this work.

This paper has been peer-reviewed.
